Novo Nordisk A/S Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Novo Nordisk A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.
View analyst ratings for Novo Nordisk A/S or view top-rated stocks.

Wall Street analysts have given Novo Nordisk A/S a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Novo Nordisk A/S wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Novo Nordisk A/S saw a decrease in short interest in August. As of August 13th, there was short interest totaling 2,890,000 shares, a decrease of 30.5% from the July 29th total of 4,160,000 shares. Based on an average daily trading volume, of 956,700 shares, the days-to-cover ratio is presently 3.0 days. Currently, 0.2% of the shares of the company are sold short.
View Novo Nordisk A/S's Short Interest.

Novo Nordisk A/S is scheduled to release its next quarterly earnings announcement on Friday, October 29th 2021.
View our earnings forecast for Novo Nordisk A/S.

Novo Nordisk A/S (NYSE:NVO) posted its earnings results on Tuesday, August, 3rd. The company reported $5.26 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.76 by $4.50. The company earned $5.35 billion during the quarter, compared to analyst estimates of $5.21 billion. Novo Nordisk A/S had a net margin of 34.17% and a trailing twelve-month return on equity of 72.72%.
View Novo Nordisk A/S's earnings history.

Novo Nordisk A/S's stock was trading at $57.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVO shares have increased by 76.9% and is now trading at $102.38.
View which stocks have been most impacted by COVID-19.

Novo Nordisk A/S announced a semi-annual dividend on Friday, August 6th. Stockholders of record on Tuesday, August 17th will be paid a dividend of $0.5571 per share on Wednesday, August 25th. This represents a yield of 1.1%. The ex-dividend date of this dividend is Monday, August 16th.
View Novo Nordisk A/S's dividend history.

Novo Nordisk A/S pays an annual dividend of $0.77 per share and currently has a dividend yield of 0.76%. The dividend payout ratio of Novo Nordisk A/S is 27.90%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 21.81% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.
View Novo Nordisk A/S's dividend history.

Novo Nordisk A/S issued an update on its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $21.80 billion-$22.42 billion, compared to the consensus revenue estimate of $21.47 billion.

372 employees have rated Novo Nordisk A/S CEO Lars Fruergaard Jørgensen on Glassdoor.com. Lars Fruergaard Jørgensen has an approval rating of 92% among Novo Nordisk A/S's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Roche (RHHBY), Pfizer (PFE), Abbott Laboratories (ABT), Eli Lilly and (LLY), AbbVie (ABBV), Novartis (NVS), Merck & Co., Inc. (MRK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Sanofi (SNY), GlaxoSmithKline (GSK), CSL (CSLLY), Zoetis (ZTS) and Regeneron Pharmaceuticals (REGN).
View all of NVO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Novo Nordisk A/S's stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.03%), Fisher Asset Management LLC (0.68%), Bank of America Corp DE (0.31%), Bank of America Corp DE (0.31%), Capital International Investors (0.23%) and Folketrygdfondet (0.20%).
View institutional ownership trends for Novo Nordisk A/S.

NVO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Northern Trust Corp, Alyeska Investment Group L.P., Wells Fargo & Company MN, Bank of America Corp DE, Bank of America Corp DE, BlackRock Inc., and First Trust Advisors LP.
View insider buying and selling activity for Novo Nordisk A/S or view top insider-selling stocks.

NVO stock was purchased by a variety of institutional investors in the last quarter, including Amundi, Folketrygdfondet, Bank of Montreal Can, Clark Capital Management Group Inc., Capital International Investors, Goldman Sachs Group Inc., Russell Investments Group Ltd., and Morgan Stanley.
View insider buying and selling activity for Novo Nordisk A/S or or view top insider-buying stocks.

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVO stock can currently be purchased for approximately $102.38.

Novo Nordisk A/S has a market capitalization of $241.08 billion and generates $19.45 billion in revenue each year. The company earns $6.46 billion in net income (profit) each year or $2.76 on an earnings per share basis.

Novo Nordisk A/S employs 45,323 workers across the globe.

The following companies are subsidiares of Novo Nordisk A/S: Aldaph SpA, Beijing Novo Nordisk Pharmaceuticals Science & Technology Co. Ltd., Calibrium, Churchill Stateside Solar Fund XIV LLC, Corvidia, Emisphere Technologies, MB2 LLC, NNE A/S, Novo Investment Pte Limited, Novo Nordisk, Novo Nordisk (China) Pharmaceuticals Co. Ltd., Novo Nordisk (Pty) Limited, Novo Nordisk B.V., Novo Nordisk Biopharm Limited, Novo Nordisk Canada Inc., Novo Nordisk Colombia SAS, Novo Nordisk Comercio Produtos Farmaceuticos Lda., Novo Nordisk Denmark A/S, Novo Nordisk Egypt LLC, Novo Nordisk Farma OY, Novo Nordisk Farma S.R.L., Novo Nordisk Farma dooel, Novo Nordisk Farmacéutica Limitada, Novo Nordisk Farmacêutica do Brasil Ltda., Novo Nordisk Health Care AG, Novo Nordisk Hellas Epe., Novo Nordisk Holding Limited, Novo Nordisk Hong Kong Limited, Novo Nordisk Hrvatska d.o.o., Novo Nordisk Hungaria Kft., Novo Nordisk Inc., Novo Nordisk India Private Limited, Novo Nordisk Kazakhstan LLP, Novo Nordisk Kenya Ltd., Novo Nordisk Lanka (PVT) Ltd, Novo Nordisk Limited, Novo Nordisk Limited Liability Company, Novo Nordisk Ltd, Novo Nordisk Mexico S.A. de C.V., Novo Nordisk Panama S.A., Novo Nordisk Pars, Novo Nordisk Peru S.A.C., Novo Nordisk Pharma (Malaysia) Sdn Bhd, Novo Nordisk Pharma (Private) Limited, Novo Nordisk Pharma (Singapore) Pte Ltd., Novo Nordisk Pharma (Taiwan) Ltd., Novo Nordisk Pharma (Thailand) Ltd., Novo Nordisk Pharma AG, Novo Nordisk Pharma Argentina S.A., Novo Nordisk Pharma EAD, Novo Nordisk Pharma GmbH, Novo Nordisk Pharma Gulf FZ-LLC, Novo Nordisk Pharma Inc., Novo Nordisk Pharma Korea Ltd., Novo Nordisk Pharma Limited, Novo Nordisk Pharma Ltd., Novo Nordisk Pharma Operations (Business Area) Sdn Bhd, Novo Nordisk Pharma Operations A/S, Novo Nordisk Pharma S.A., Novo Nordisk Pharma SARL, Novo Nordisk Pharma SAS, Novo Nordisk Pharma d.o.o., Novo Nordisk Pharma d.o.o. Belgrade (Serbia), Novo Nordisk Pharmaceutical Industries LP, Novo Nordisk Pharmaceutical Services Sp. z o.o., Novo Nordisk Pharmaceuticals (Philippines) Inc., Novo Nordisk Pharmaceuticals Ltd., Novo Nordisk Pharmaceuticals Pty. Ltd., Novo Nordisk Pharmatech A/S, Novo Nordisk Production SAS, Novo Nordisk Production Support LLC, Novo Nordisk Produção Farmacêutica do Brasil Ltda., Novo Nordisk Region AAMEO and LATAM A/S, Novo Nordisk Region Europe A/S, Novo Nordisk Region Japan & Korea A/S, Novo Nordisk Research Center Indianapolis Inc., Novo Nordisk Research Center Seattle Inc., Novo Nordisk S.P.A., Novo Nordisk Saglik Ürünleri Tic. Ltd. Sti., Novo Nordisk Scandinavia AB, Novo Nordisk Scandinavia AS, Novo Nordisk Service Centre (India) Pvt. Ltd., Novo Nordisk Slovakia s.r.o., Novo Nordisk Tunisie SARL, Novo Nordisk US Bio Production Inc., Novo Nordisk US Holdings Inc., Novo Nordisk Ukraine LLC, Novo Nordisk Venezuela Casa de Representacion C.A., Novo Nordisk d.o.o., Novo Nordisk s.r.o., PT. Novo Nordisk Indonesia, S.A. Novo Nordisk Pharma N.V., UAB Novo Nordisk Pharma, Xellia Pharmaceuticals, and Ziylo.

Novo Nordisk A/S was founded in 1923.

The official website for Novo Nordisk A/S is www.novonordisk.com.

Novo Nordisk A/S is headquartered at Novo Alle, Bagsvaerd G7, 2880.

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at (454) 444-8888 or via email at [email protected]